Kristin Price, MS, CGC

Product leader @guardanthealth. Specializing in ctDNA & developing tools to support more personalized oncology care.

[Timothy Newhook @timnewhook19]

👀👇our early experience w/periop #ctDNA for pts w/ #livermetastases from #colorectalcancer. Some “cleared” by surgery! Do you use this biomarker in care of pts w/CLM?
@VautheyMD @skopetz @colontown @manjuggm @MDAndersonNews @AnnalsofSurgery #oncsurgery

https://t.co/3csj8WyFAn

[Kristin Price, MS, CGC @k_sedge]

Less patients getting unnecessary chemotherapy is a HUGE win. So exciting to see this clinical utility data from ctDNA MRD testing.

[NEJM @NEJM]

DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 https://t.co/xXjXyPXRC9

[Kristin Price, MS, CGC @k_sedge]

Congratulations to Dr. Kobayashi, Dr. Jänne and team @DanaFarber on the discovery of a silent mutation required to produce a functional KRAS Q61K & the @Nature pub. Thanks for letting me and @GuardantHealth be a part of this very cool work! https://t.co/1cxh6diR3M

[Dr. Bishoy M. Faltas @FaltasLab]

Very proud of our new paper: Common germline-somatic variant interactions in advanced urothelial cancer https://t.co/TgGSgAnecG Tweetorial to follow.

[Kristin Price, MS, CGC @k_sedge]

@GCCarolKo @minoritygenetic @NSGC_SNG_SIG Ive started new and intimidating roles many times in my career- set up into meetings with everyone you will collaborate with in your new role. Make yourself known to all the MDs and staff you will work with- articulate your value and ask how you can best work together

[Kristin Price, MS, CGC @k_sedge]

A great story of hope. We have so far to go to improve cancer treatment, but there have been amazing improvements giving patients more time with they people they love (and more quality time on less toxic drugs). This is what motivates me. https://t.co/paeOyOWJPU

[Kristin Price, MS, CGC @k_sedge]

@aparna1024 @MGHCancerCenter @drlouiseivers @GlobalHealthMGH Congratulations @aparna1024 !!!

[Kristin Price, MS, CGC @k_sedge]

Key to strong performance w/out tissue is the multiomic nature of the assay. Adding methylation to genomic analysis increased sensitivity by 36% in the setting of a single post-tx draw- it is sort of like adding more needles to the haystack when looking for signs of MRD!

[Kristin Price, MS, CGC @k_sedge]

Congrats to @aparna1024 @TedHong9 @KlempnerSam & MGH team on the CCR pub showing Guardant Reveal plasma-only MRD assay for #CRC has comp sensitivity & specificity to tumor-informed assays. No tissue need & fast TAT has great potential to help more pts. https://t.co/XZkQjQwGL5

[Guardant Health @GuardantHealth]

We’re excited to launch Guardant Reveal, the first blood-only #liquidbiopsy test for residual disease and recurrence monitoring of early-stage #colorectalcancer patients. #MRD https://t.co/3GsP9X1vgu

[MGH Thoracic Oncology @MGHThoracicOnc]

Pralsetinib (BLU-667), #RET inhibitor is now FDA approved, further expanding treatment options for our patients. Congratulations to @JustinGainor and co-investigators, and thanks to all patients and families for their contributions! https://t.co/8PL2ZGFSiD #NSCLC #LCSM

[Balazs Halmos @BalazsHalmosMD]

non-smoker in 40s with egfr/alk/ros -/ pd-l1 high+ lung adeno from OSH after chemo/io failure w leptomeningeal disease, pall care discussed
?Can we just send 2 tubes of blood?
Results:👇
We should rename NGS➡️ NMP (no malpractice) - might make it easier to remember to order it...

[Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD]

Important to remember to #Test for #Actionable Mutations using #NGS in patients with metastatic #NSCLC prior to using immunotherapy. #Plasma is a meaningful way to test. There are important efficacy and toxicity implications. Nicely summarized by @Tony_Calles et al #ASCO20

[Joshua Bauml, MD @Jbauml]

This is fantastic news! We now have access to a highly active RET inhibitor. https://t.co/nKEDN744FJ

[Kristin Price, MS, CGC @k_sedge]

Also important to remember that @JSabari & team showed that pts with MET exon 14 skipping mutations have poor response to ICB. ORR was 17% and the median PFS was 1.9 months. Responses were not enriched in tumors with PD-L1 expression ≥50% nor high TMB.

[Kristin Price, MS, CGC @k_sedge]

Excited to see the approval of #capmatinib for #METex14 skipping NSCLC. Data from GEOMETRY shows higher ORR in first-line setting (68% 1L and 41% 2/3L) - highlights importance of early molecular testing. Thanks @BeccaHeistMD and @MGHThoracicOnc for helping to make this happen!!

[Kristin Price, MS, CGC @k_sedge]

Great to see the PROfound trial in #NEJM showing benefit for olaparib in #mCRPC pts w/ #BRCA1/2 and #ATM muts. It will be important to ensure all patients get tested- somatic & germline. Interested to see response breakdown by mutation type. #GCchat https://t.co/SvrWe40cYj

[Lecia Sequist, MD, MPH, FASCO @LeciaSequist]

Definitely time to add #MetExon14 to testing at diagnosis for all lung cancer patients? I say yes!

[Kristin Price, MS, CGC @k_sedge]

Encorafenib/Cetuximab Combo now FDA approved for #BRAF pos #mCRC. Data we published last year with @cotahealthcare showed that testing rates for BRAF in 2017 were around 50%. Let's make sure more patients get access to comprehensive testing in 2020. https://t.co/IA2mnE5SUh

[Kristin Price, MS, CGC @k_sedge]

@KlempnerSam @MGHMedicine @MGHCancerCenter Thanks for taking care of all of us Bostonians @KlempnerSam ! Stay safe out there!